FrancophonIA/ELRC3.0 huggingface dataset:
English: Repeated-dose toxicity studies (treatment schedule of 3 weeks on/1 week off) of up to 27 weeks' duration in rats and up to 39 weeks' duration in dogs, revealed the hepatobiliary system (proliferative changes, cholestasis, sand-like gallbladder calculi, and inspissated bile) as the primary target organ of toxicity of ribociclib.
Danish: Studier af toksicitet efter gentagne doser (behandlingsplan med 3 ugers behandling og 1 uge uden) af op til 27 ugers varighed hos rotter og op til 39 ugers varighed hos hunde viste, at det hepatobiliære system (proliferative forandringer, cholestase, sandlignende sten i galdeblæren og galdegrød) var det primære målorgan for toksicitet af ribociclib.
English: A starting dose of 400 mg is recommended in patients with severe renal impairment (see section 5.2).
Danish: En startdosis på 400 mg anbefales til patienter med svært nedsat nyrefunktion (se pkt.
English: The pharmacokinetics of ribociclib were investigated in patients with advanced cancer following oral daily doses of 50 mg to 1200 mg.
Danish: Ribociclibs farmakokinetik blev undersøgt hos patienter med fremskreden kræft efter daglige orale doser på 50 mg til 1.200 mg.
English: CI=confidence interval, NE=not estimable, N=number of patients; p-value is obtained from the one-sided log-rank test stratified by lung and/or liver metastases, prior chemotherapy for advanced disease, and endocrine partner per IRT (interactive response technology).
Danish: CI = konfidence-interval, NE = ikke estimerbar, N = antal patienter; p-værdien stammer fra den ensidede log-rank test stratificeret ud fra lunge- og/eller levermetastaser, før kemoterapi ved fremskreden sygdom og endokrin partner per IRT (interaktiv respons-teknologi).
English: ECGs with QTcF >500 msec
Danish: EKG'er med QTcF >500 ms
English: Based on a population pharmacokinetic analysis that included 160 breast cancer patients with normal hepatic function and 47 patients with mild hepatic impairment, mild hepatic impairment had no effect on the exposure of ribociclib, further supporting the findings from the dedicated hepatic impairment study.
Danish: På baggrund af en populationsfarmakokinetisk analyse, der omfattede 160 brystkræft-patienter med normal leverfunktion og 47 patienter med let nedsat leverfunktion, havde let nedsat leverfunktion ingen effekt på eksponeringen for ribociclib, hvilket yderligere understøtter fundene fra studiet omhandlende nedsat leverfunktion.
English: Kisqali can be taken with or without food (see section 4.5).
Danish: Kisqali kan tages med eller uden mad (se pkt.
English: Exposure to ribociclib in animals in the toxicity studies was generally less than or equal to that observed in patients receiving multiple doses of 600 mg/day (based on AUC).
Danish: Eksponering for ribociclib hos dyr i toksicitetsstudierne var generelt mindre end eller lig med den eksponering, der blev observeret hos patienter, som fik flere doser af 600 mg/dag (baseret på AUC).
English: Take Kisqali once daily at the same time each day, preferably in the morning.
Danish: Tag Kisqali én gang daglig på samme tidspunkt hver dag og helst om morgenen.
English: Eye disorders Lacrimation increased, dry eye
Danish: Øjne Øget tåresekretion, øjentørhed
English: • Hair loss or hair thinning (alopecia)
Danish: • Hårtab eller tyndere hår (alopeci)
English: Phase II conjugates of ribociclib phase I metabolites involved N-acetylation, sulfation, cysteine conjugation, glycosylation and glucuronidation.
Danish: Fase II-konjugater af fase I- ribociclib-metabolitter involverede N-acetylering, sulfatering, cysteinkonjugering, glykosylering og glukuronidering.
English: These are known to inhibit cytochrome CYP3A4 enzymes and may increase the exposure to ribociclib.
Danish: Disse er kendt for at hæmme cytochrom CYP3A4-enzymer og kan øge eksponeringen for ribociclib.
English: There was no statistically significant difference in overall survival (OS) between the Kisqali plus letrozole arm and the placebo plus letrozole arm (HR 0.746 [95% CI: 0.517, 1.078]).
Danish: Der var ingen statistisk signifikant forskel i samlet overlevelse (OS) mellem Kisqali plus letrozolarmen og placebo plus letrozol-armen (HR 0,746 [95 % CI: 0,517; 1,078]).
English: Blood and lymphatic system disorders Neutropenia, leukopenia, anaemia
Danish: Blod og lymfesystem Neutropeni, leukopeni, anæmi
English: What Kisqali contains - The active substance is ribociclib.
Danish: Kisqali indeholder: - Aktivt stof: ribociclib.
English: Number of events - n [%] Median OS [months] (95% CI) NE (NE, NE)
Danish: Antal hændelser - n [%] Median OS [måneder] (95% CI)
English: Ribociclib and its metabolites are eliminated mainly via faeces, with a small contribution of the renal route.
Danish: Ribociclib og dets metabolitter elimineres overvejende via fæces, med et lille bidrag ad den renale vej.
English: The outer carton of the Kisqali pack includes a “calendar tool” which allows you to track your daily Kisqali dose by marking off a circle for every tablet you take over the 28-day cycle.
Danish: På yderpakningen for Kisqali er der et kalenderværktøj, hvor du kan følge din daglige dosis af Kisqali ved at afkrydse en cirkel for hver tablet, du tager i løbet af behandlingsserien på 28 dage.
English: Treatment with Kisqali should be initiated only in patients with QTcF values less than 450 msec. ECG should be repeated at approximately day 14 of the first cycle and at the beginning of the second cycle, then as clinically indicated (see sections 4.2 and
Danish: Behandling med Kisqali bør kun indledes hos patienter med QTcF-værdier, der er mindre end 450 ms. EKG-optagelser skal gentages på ca. dag 14 i den første serie og i starten af den anden serie og herefter ved klinisk behov (se pkt.
English: Your doctor may also decide to stop treatment with Kisqali permanently.
Danish: Lægen kan også beslutte helt at stoppe behandlingen med Kisqali.
English: Log-rank test and Cox model are stratified by lung and/or liver metastasis, prior chemotherapy for advanced disease, and endocrine combination partner per IRT
Danish: Log-rank test og Cox model er stratificeret som lunge- og/eller levermetastaser, før kemoterapi for fremskreden sygdom og endokrin kombinationspartner per IRT.
English: Overall response rate (ORR)
Danish: Samlet responsrate (ORR)
English: Based on a population pharmacokinetic analysis that included 77 patients with normal renal function (eGFR ≥90 ml/min/1.73 m2), 76 patients with mild renal impairment (eGFR 60 to
Danish: På baggrund af en populationsfarmakokinetisk analyse, der omfattede 77 patienter med normal nyrefunktion (eGFR ≥90 ml/min/1,73 m2), 76 patienter med let nedsat nyrefunktion (eGFR 60 til
English: Patients enrolled in this study had a median age of 63 years (range 31 to 89).
Danish: Patienterne, der var inkluderet i dette studie, havde en medianalder på 63 år (interval: 31 til 89).
English: For patients who had their ribociclib dose reduced to 400 mg once daily, the increase of the steady-state Cmax and AUC was estimated to be 1.4- and 2.1-fold, respectively.
Danish: Hos patienter, der fik reduceret deres ribociclib-dosis til 400 mg én gang daglig, blev steady state Cmax og AUC estimeret til at stige henholdsvis 1,4 og 2,1 gange.
English: If you stop taking Kisqali
Danish: Hvis du holder op med at tage Kisqali
English: Nervous system disorders Headache, dizziness
Danish: Nervesystemet Hovedpine, svimmelhed
English: However, monitoring of ribociclib-related AEs is recommended.
Danish: Det anbefales dog at monitorere for ribociclib-relaterede bivirkninger.
English: Pregnancy and women of childbearing potential
Danish: Graviditet og kvinder, der kan blive gravide
English: Grade 4**
Danish: Grad 4**
English: Review of ECG data showed 14 patients (1.3%) had >500 msec post-baseline QTcF value, and 59 patients (5.6%) had a >60 msec increase from baseline in QTcF intervals.
Danish: Gennemgang af EKG-data viste, at 14 patienter (1,3 %) havde en post-baseline-QTcF-værdi >500 ms, og 59 patienter (5,6 %) havde forlænget QTcF-interval >60 ms i forhold til baseline.
English: Tablet core: microcrystalline cellulose; crospovidone type A; low-substituted hydroxypropylcellulose; magnesium stearate; colloidal anhydrous silica.
Danish: Tabletkerne: mikrokrystallinsk cellulose, crospovidon type A, lav-substitueret hydroxypropylcellulose, magnesiumstearat, kolloid vandfri silica.
English: The most common ADRs and the most common grade 3/4 ADRs (reported at a frequency ≥20% and ≥2%, respectively) in the pooled dataset for which the frequency for Kisqali plus any combination exceeds the frequency for placebo plus any combination were infections, neutropenia, leukopenia, headache, cough, nausea, fatigue, diarrhoea, vomiting, constipation, alopecia and rash, and infections, neutropenia, leukopenia, anaemia, abnormal liver function tests, lymphopenia, hypophosphataemia and vomiting respectively.
Danish: De mest almindelige bivirkninger og de mest almindelige bivirkninger af grad 3/4 (rapporteret med en hyppighed på henholdsvis ≥20 % og ≥2 %) i det sammenlagte datasæt, for hvilke hyppigheden for Kisqali plus enhver kombination overstiger hyppigheden for placebo plus enhver kombination, var henholdsvis infektioner, neutropeni, leukopeni, hovedpine, hoste, kvalme, træthed, diarré, opkastning, obstipation, alopeci og udslæt og infektioner, neutropeni, leukopeni, anæmi, unormale levertal, lymfopeni, hypofosfatæmi og opkastning.
English: Iron oxide black (E172) Iron oxide red (E172) Soya lecithin (E322) Polyvinyl alcohol (partially hydrolysed) Talc
Danish: Sort jernoxid (E 172) Rød jernoxid (E 172) Sojalecithin (E322) Polyvinylalkohol (delvis hydrolyseret) Talcum
English: Grade 3* febrile neutropenia**
Danish: Febril neutropeni** af grad 3*
English: Grade 3 or 4 increases in ALT (9.7% versus 1.5%) and AST (6.7% versus 2.1%) were reported in the Kisqali and placebo arms, respectively.
Danish: Der blev rapporteret grad 3 eller 4-stigninger i ALAT-niveauet (9,7 % versus 1,5 %) og ASAT-niveauet (6,7 % versus 2,1 %) i henholdsvis Kisqaliog placebo-armene.
English: Light greyish violet, unscored, round, curved with bevelled edges (approximate diameter: 11.1 mm), debossed with “RIC” on one side and “NVR” on the other side.
Danish: Lys gråviolet, rund, buet med facetslebne kanter og uden delekærv (ca. diameter: 11,1 mm), præget med “RIC” på den ene side og “NVR” på den anden side.
English: AST and/or ALT elevations from baseline**, without increase in total bilirubin above 2 x ULN
Danish: Stigning i ASATog/eller ALATniveauet i forhold til baseline**, uden stigning i totalbilirubinniveauet til over 2 x ULN
English: Patients enrolled in this study had a median age of 62 years (range 23 to 91).
Danish: Patienterne, der var inkluderet i dette studie, havde en medianalder på 62 år (interval: 23 til 91).
English: In the Kisqali arm 43.7% of patients had received chemotherapy in the neoadjuvant or adjuvant setting and 52.4% had received antihormonal therapy in the neoadjuvant or adjuvant setting prior to study entry.
Danish: I Kisqali-armen havde 43,7 % af patienterne fået neoadjuverende eller adjuverende kemoterapi, og 52,4 % havde fået neoadjuverende eller adjuverende antihormonbehandling forud for indtrædelsen i studiet.
English: The tablets should be swallowed whole and should not be chewed, crushed or split prior to swallowing.
Danish: Tabletterne skal synkes hele og må ikke tygges, knuses eller deles, før de synkes.
English: • Analgesics such as alfentanil and fentanyl.
Danish: • Smertestillende lægemidler, fx alfentanil og fentanyl.
English: Co-administration of ribociclib with medicinal products that elevate the gastric pH was not evaluated in a clinical study; however, altered ribociclib absorption was not observed in population pharmacokinetic and non-compartmental pharmacokinetic analyses.
Danish: Samtidig administration af ribociclib og lægemidler, der hæver gastrisk pH, blev ikke evalueret i et klinisk studie, men der blev dog hverken observeret ændret absorption af ribociclib i den populationsfarmakokinetiske eller non-kompartment-farmakokinetiske analyse.
English: The geometric mean plasma effective half-life (based on accumulation ratio) was 32.0 hours (63% CV) and the geometric mean apparent oral clearance (CL/F) was 25.5 l/hr (66% CV) at steady state at 600 mg in patients with advanced cancer.
Danish: Den geometriske middelværdi af den effektive plasmahalveringstid (baseret på akkumuleringsforholdet) var 32,0 timer (63 % CV), og den geometriske middelværdi af den tilsyneladende orale clearance (CL/F) var 25,5 l/t (66 % CV) ved steady state ved 600 mg hos patienter med fremskreden kræft.
English: Each film-coated tablet contains ribociclib succinate equivalent to 200 mg ribociclib.
Danish: Hver filmovertrukket tablet indeholder ribociclibsuccinat svarende til 200 mg ribociclib.
English: In study F2301 21.2% had bone-only disease and 60.5% had visceral disease.
Danish: I studie F2301 havde 21,2 % knoglesygdom alene, og 60,5 % havde visceral sygdom.
English: Due to inter-patient variability, the recommended dose adjustments may not be optimal in all patients, therefore close monitoring of signs of toxicity is recommended.
Danish: På grund af variabilitet mellem patienter, er de anbefalede dosisjusteringer ikke nødvendigvis optimale hos alle patienter.
English: Grade 1 or 2* (ANC
Danish: Grad 1 eller 2* (ANC
English: Before you take Kisqali, tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines or supplements obtained without a prescription, because these may influence the effect of Kisqali.
Danish: Fortæl lægen eller apotekspersonalet, før du tager Kisqali, hvis du tager anden medicin - dette gælder også håndkøbslægemidler eller kosttilskud, der er købt uden recept - eller har gjort det for nylig, da disse muligvis kan påvirke virkningen af Kisqali.
English: Hazard Ratio = 0.568; 95% CI [0.457, 0.704] Kaplan-Meier median - Ribociclib: 25.3 months; Placebo: 16.0 months Log rank p-value = 9.63*10^(-8)
Danish: Hazard ratio = 0,568; 95 % CI [0,457; 0,704] Kaplan-Meier-median - Ribociclib: 25,3 måneder; Placebo: 16,0 måneder Log rank p-værdi = 9,63*10^(-8)
English: Ribociclib was extensively metabolised, with unchanged drug accounting for 17.3% and 12.1% of the dose in faeces and urine, respectively.
Danish: Ribociclib blev metaboliseret i høj grad. Uomdannet lægemiddel udgør henholdsvis 17,3 % og 12,1 % af dosis i fæces og urin.
English: The geometric mean apparent plasma terminal half-life (T1/2) of ribociclib ranged from 29.7 to 54.7 hours and the geometric mean CL/F of ribociclib ranged from 39.9 to 77.5 l/hr at 600 mg across studies in healthy subjects.
Danish: Den geometriske middelværdi af den tilsyneladende terminale plasmahalveringstid (T1/2) af ribociclib var i intervallet fra 29,7 til 54,7 timer, og den geometriske middelværdi CL/F af ribociclib var i intervallet fra 39,9 til 77,5 l/t ved 600 mg på tværs af studier hos raske forsøgspersoner.
English: Among the patients who had grade 3 or 4 ALT/AST elevation, the median time to onset was 85 days for the Kisqali plus any combination arms.
Danish: Blandt de patienter, der havde forhøjet ALAT- eller ASAT-niveau af grad 3 eller 4, var mediantiden til fremkomst 85 dage for armene med Kisqali plus enhver kombination.
English: No of events
Danish: Antal hændelser
English: In vivo studies using patient-derived oestrogen receptor-positive breast cancer xenograft model combinations of ribociclib and antioestrogens (i.e. letrozole) resulted in superior tumour growth inhibition with sustained tumour regression and delayed tumour regrowth after stopping dosing compared to each substance alone.
Danish: I in vivo-studier, hvor der blev anvendt en xenograftmodel af patient-afledt østrogenreceptor-positiv brystkræft, resulterede kombinationer af ribociclib og antiøstrogener (dvs. letrozol) i overlegen hæmning af tumorvækst med vedvarende tumorregression og udskudt tumorgenvækst efter ophør med dosering sammenlignet med hvert stof alene.
English: Dose reduction due to adverse events, regardless of causality, occurred in 37.3% of patients receiving Kisqali in the phase III clinical studies regardless of the combination and permanent discontinuation was reported in 7.0% of patients receiving Kisqali and any combination in the phase III clinical studies.
Danish: Dosisreduktion som følge af bivirkninger, uanset årsagssammenhæng, skete hos 37,3 % af de patienter, der fik Kisqali i de kliniske fase III-studier uanset kombination, og permanent seponering som følge af bivirkninger blev rapporteret hos 7,0 % af de patienter, der fik Kisqali og enhver kombination i de kliniske fase III-studier.
English: Kisqali 200 mg film-coated tablets ribociclib
Danish: Kisqali 200 mg filmovertrukne tabletter ribociclib
English: Ribociclib did not inhibit OAT1, OAT3 or MRP2 at clinically relevant concentrations in vitro.
Danish: Ribociclib hæmmede ikke OAT1, OAT3 eller MRP2 ved klinisk relevante koncentrationer in vitro.
English: You should take Kisqali once daily every day at the same time, preferably in the morning.
Danish: Du skal tage Kisqali en gang daglig på samme tidspunkt hver dag og helst om morgenen.
English: In study E2301 40.2% of patients had de novo metastatic disease, 23.7% had bone-only disease, and 56.7% had visceral disease.
Danish: I studie E2301 havde 40,2 % af patienterne de novo metastatisk sygdom, 23,7 % havde knoglesygdom alene, og 56,7 % havde visceral sygdom.
English: The overall safety evaluation of Kisqali is based on the pooled dataset from 1,065 patients who received Kisqali in combination with endocrine therapy (N=582 in combination with an aromatase inhibitor and N=483 in combination with fulvestrant) and who were included in the randomised, double-blind, placebo-controlled phase III clinical studies (MONALEESA-2, MONALEESA-7 NSAI subgroup and MONALEESA-3) in HR-positive, HER2-negative advanced or metastatic breast cancer.
Danish: Den samlede sikkerhedsvurdering af Kisqali er baseret på datasættet med sammenlagte data fra 1.065 patienter, der fik Kisqali i kombination med endokrin behandling (N=582 i kombination med en aromatasehæmmer, og N=483 i kombination med fulvestrant), og som var inkluderet i de randomiserede, dobbeltblindede, placebokontrollerede kliniske fase III-studier (MONALEESA-2, MONALEESA-7 NSAI-subgruppe og MONALEESA-3) af HR-positiv, HER2-negativ, fremskreden eller metastatisk brystkræft.
English: • If you have a fever, sore throat or mouth ulcers due to infections (signs of a low level of white blood cells).
Danish: • Hvis du har feber, ondt i halsen eller sår i munden på grund af infektioner (tegn på et lavt niveau af hvide blodlegemer).
English: Clinical benefit rate b a
Danish: Rate for klinisk fordel b a
English: Neutropenia was the most frequently reported adverse drug reaction (73.7%) and a grade 3 or 4 decrease in neutrophil counts (based on laboratory findings) was reported in 58.6% of patients receiving Kisqali plus any combination in the phase III studies.
Danish: Neutropeni var den hyppigst rapporterede bivirkning (73,7 %), og et fald i neutrofiltal af grad 3 eller 4 (baseret på laboratoriefund) blev rapporteret hos 58,6 % af patienter, der fik Kisqali plus enhver kombination i fase III-studierne.
English: Other toxicities
Danish: Andre toksiciteter
English: Drug-drug interaction studies between ribociclib and oral contraceptives have not been conducted (see section 4.6)
Danish: Der er ikke udført lægemiddelinteraktionsstudier med ribociclib og orale kontraceptiva (se pkt.
English: Patients with moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C) can have increased (less than 2-fold) exposure to ribociclib and the starting dose of 400 mg Kisqali once daily is recommended (see section 5.2).
Danish: Patienter med moderat nedsat (Child-Pugh klasse B) og svært nedsat (Child-Pugh klasse C) leverfunktion kan have forhøjet eksponering for ribociclib (mindre end 2 gange), og der anbefales en startdosis af Kisqali på 400 mg én gang daglig (se pkt.
English: The median time to resolution (to normalisation or grade ≤2) was 22 days in the Kisqali plus any combination arms.
Danish: Mediantiden til bedring (til normalisering eller grad ≤2) var 22 dage i armene med Kisqali plus enhver kombination.
English: In the phase III clinical studies, hepatobiliary toxicity events occurred in a higher proportion of patients in the Kisqali plus any combination arms compared with the placebo plus any combination arms (23.2% versus 16.5%, respectively), with more grade 3/4 adverse events reported in the patients treated with Kisqali plus any combination (11.4% versus 5.4%, respectively).
Danish: I de kliniske fase III-studier forekom hændelser med hepatobiliær toksicitet hos en højere andel patienter i armene med Kisqali plus enhver kombination sammenlignet med armene med placebo plus enhver kombination (henholdsvis 23,2 % versus 16,5 %), med flere hændelser af grad 3/4 rapporteret hos patienter, der blev behandlet med Kisqali plus enhver kombination (henholdsvis 11,4 % versus 5,4 %).
English: In vitro and in vivo studies indicated ribociclib is eliminated primarily via hepatic metabolism mainly via CYP3A4 in humans.
Danish: In vitro- og in vivo-studier indikerede, at ribociclib primært elimineres via hepatisk metabolisme og primært via CYP3A4 hos mennesker.
English: Please refer to the Summary of Product Characteristics (SmPC) of the aromatase inhibitor for additional details.
Danish: Se produktresuméet (SmPC) for aromatasehæmmeren for yderligere oplysninger.
English: Data from a clinical study in patients with breast cancer indicated that tamoxifen exposure was increased approximately 2-fold following co-administration of ribociclib and tamoxifen.
Danish: Data fra et klinisk studie hos patienter med brystkræft tydede på, at tamoxifen-eksponering cirka fordobledes efter samtidig administration af ribociclib og tamoxifen.
English: • Tiredness, itchy yellow skin or yellowing of the whites of your eyes, nausea or vomiting, loss of appetite, pain in the upper right side of the belly (abdomen), dark or brown urine, bleeding or bruising more easily than normal (these may be signs of a liver problem).
Danish: • Træthed, kløende gul hud eller gulfarvning af det hvide i øjnene, kvalme eller opkastning, appetitløshed, smerter i den øvre højre del af maveområdet (abdomen), mørk eller brun urin, blødning eller får blå mærker lettere end normalt (dette kan være tegn på et leverproblem).
English: • Skin reddening (erythema)
Danish: • Rødmen på huden (erytem)
English: • Serious infection with increased heart rate, shortness of breath or rapid breathing, fever and chills (these may be signs of sepsis which is an infection in the blood system which may be life threatening).
Danish: • Alvorlig infektion med høj puls, åndenød eller hurtig vejrtrækning, feber og kulderystelser (disse kan være tegn på sepsis, også kaldet blodforgiftning, der er en infektion i blodsystemet, som kan være livstruende).
English: • Medicines used to prevent the rejection of an organ transplant such as tacrolimus, sirolimus and ciclosporin (also used to treat inflammation in rheumatoid arthritis and psoriasis).
Danish: • Lægemidler, der anvendes til at forebygge, at kroppen afstøder transplanterede organer, fx tacrolimus, sirolimus og ciclosporin (bruges også til at behandle inflammation ved leddegigt og psoriasis).
English: Kisqali contains soya lecithin.
Danish: Kisqali indeholder sojalecithin.
English: Do not use this medicine after the expiry date which is stated on the carton and the blister.
Danish: Brug ikke lægemidlet efter den udløbsdato, der står på pakningen og blisteren efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned.
English: Concomitant administration of ribociclib at the 600 mg dose with the following CYP3A4 substrates should be avoided: alfuzosin, amiodarone, cisapride, pimozide, quinidine, ergotamine, dihydroergotamine, quetiapine, lovastatin, simvastatin, sildenafil, midazolam, triazolam.
Danish: Det bør undgås at administrere ribociclib i dosen 600 mg samtidigt med følgende CYP3A4-substrater: alfuzosin, amiodaron, cisaprid, pimozid, quinidin, ergotamin, dihydroergotamin, quetiapin, lovastatin, simvastatin, sildenafil, midazolam og triazolam.